• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

比较前列腺癌和良性前列腺增生患者中 CD33 pSTAT3 髓系来源抑制细胞和 IL-17 淋巴细胞的频率。

Comparing the frequency of CD33 pSTAT3 myeloid-derived suppressor cells and IL-17 lymphocytes in patients with prostate cancer and benign prostatic hyperplasia.

机构信息

Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran.

Department of Pathology, Shahrekord University of Medical Sciences, Shahrekord, Iran.

出版信息

Cell Biol Int. 2021 Oct;45(10):2086-2095. doi: 10.1002/cbin.11651. Epub 2021 Jun 29.

DOI:10.1002/cbin.11651
PMID:34184811
Abstract

Prostate cancer (PCa) is one of the most epidemic types of cancer in men. The tumor microenvironment (TME) of PCa is involved in the emergence of immunosuppressive factors such as myeloid-derived suppressor cells (MDSC), which regulate the immune system by several mechanisms, including interleukin (IL)-10 production. On the other hand, IL-17 helper T cells (Th17) induce MDSCs and chronic inflammation in TME by producing IL-17. This study demonstrated that the frequency of CD33 pSTAT3 MDSC and IL-17 lymphocyte as well as IL-10 messenger RNA (mRNA) expression were significantly higher in the PCa patients than in the benign prostatic hyperplasia (BPH) group. Moreover, there was no significant relationship between the frequency of CD33 pSTAT3 MDSC, and IL-17 lymphocyte with Gleason scores in the PCa group. We suggested that the higher frequency of CD33 pSTAT3 MDSC and IL-17 lymphocyte and the more frequent expression of IL-10 mRNA in PCa patients may play roles in tumor progression from BPH to PCa.

摘要

前列腺癌 (PCa) 是男性中最常见的癌症类型之一。PCa 的肿瘤微环境 (TME) 涉及免疫抑制因子的出现,如髓系来源的抑制细胞 (MDSC),它们通过多种机制调节免疫系统,包括白细胞介素 (IL)-10 的产生。另一方面,IL-17 辅助 T 细胞 (Th17) 通过产生 IL-17 在 TME 中诱导 MDSC 和慢性炎症。本研究表明,与良性前列腺增生 (BPH) 组相比,PCa 患者的 CD33 pSTAT3 MDSC 和 IL-17 淋巴细胞以及白细胞介素-10 信使 RNA (mRNA) 表达的频率明显更高。此外,在 PCa 组中,CD33 pSTAT3 MDSC 和 IL-17 淋巴细胞的频率与 Gleason 评分之间没有显著关系。我们认为,PCa 患者中 CD33 pSTAT3 MDSC 和 IL-17 淋巴细胞的较高频率以及 IL-10 mRNA 的更频繁表达可能在从 BPH 到 PCa 的肿瘤进展中发挥作用。

相似文献

1
Comparing the frequency of CD33 pSTAT3 myeloid-derived suppressor cells and IL-17 lymphocytes in patients with prostate cancer and benign prostatic hyperplasia.比较前列腺癌和良性前列腺增生患者中 CD33 pSTAT3 髓系来源抑制细胞和 IL-17 淋巴细胞的频率。
Cell Biol Int. 2021 Oct;45(10):2086-2095. doi: 10.1002/cbin.11651. Epub 2021 Jun 29.
2
Immunosuppressive role of CD11b CD33 HLA-DR myeloid-derived suppressor cells-like blast subpopulation in acute myeloid leukemia.CD11b CD33 HLA-DR 髓系来源抑制性细胞样 blast 亚群在急性髓系白血病中的免疫抑制作用。
Cancer Med. 2020 Oct;9(19):7007-7017. doi: 10.1002/cam4.3360. Epub 2020 Aug 11.
3
Circulating myeloid-derived suppressor cells: An independent prognostic factor in patients with breast cancer.循环髓系来源的抑制细胞:乳腺癌患者的独立预后因素。
J Cell Physiol. 2019 Apr;234(4):3515-3525. doi: 10.1002/jcp.26896. Epub 2018 Oct 26.
4
CD45CD33CD11b myeloid-derived suppressor cells suppress CD8 T cell activity via the IL-6/IL-8-arginase I axis in human gastric cancer.CD45CD33CD11b 髓系来源的抑制细胞通过 IL-6/IL-8-精氨酸酶 I 轴抑制人胃癌中的 CD8 T 细胞活性。
Cell Death Dis. 2018 Jul 9;9(7):763. doi: 10.1038/s41419-018-0803-7.
5
Expression Levels of IL-17A, IL-17F, IL-17RA, and IL-17RC in Prostate Cancer with Taking into Account the Histological Grade according to Gleason Scale in Comparison to Benign Prostatic Hyperplasia: In Search of New Therapeutic Options.白细胞介素-17A、白细胞介素-17F、白细胞介素-17RA 和白细胞介素-17RC 在前列腺癌中的表达水平,同时考虑到根据格里森评分的组织学分级与良性前列腺增生的比较:寻找新的治疗选择。
J Immunol Res. 2020 May 25;2020:4910595. doi: 10.1155/2020/4910595. eCollection 2020.
6
Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells.肝癌相关成纤维细胞通过促进髓系来源抑制细胞的产生来增强免疫抑制。
Oncogene. 2017 Feb 23;36(8):1090-1101. doi: 10.1038/onc.2016.273. Epub 2016 Sep 5.
7
TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients.靶向TLR9的STAT3沉默消除了前列腺癌患者髓源性抑制细胞的免疫抑制活性。
Clin Cancer Res. 2015 Aug 15;21(16):3771-82. doi: 10.1158/1078-0432.CCR-14-3145. Epub 2015 May 12.
8
Frequency of IL-10+CD19+ B cells in patients with prostate cancer compared to patients with benign prostatic hyperplasia.与良性前列腺增生患者相比,前列腺癌患者中 IL-10+CD19+B 细胞的频率。
Afr Health Sci. 2020 Sep;20(3):1264-1272. doi: 10.4314/ahs.v20i3.31.
9
TGF-β Enhances the Anti-inflammatory Effect of Tumor- Infiltrating CD33+11b+HLA-DR Myeloid-Derived Suppressor Cells in Gastric Cancer: A Possible Relation to MicroRNA-494.TGF-β 增强肿瘤浸润性 CD33+11b+HLA-DR 髓系来源抑制细胞在胃癌中的抗炎作用:可能与 microRNA-494 有关。
Asian Pac J Cancer Prev. 2020 Nov 1;21(11):3393-3403. doi: 10.31557/APJCP.2020.21.11.3393.
10
Hepatitis C virus-induced myeloid-derived suppressor cells regulate T-cell differentiation and function via the signal transducer and activator of transcription 3 pathway.丙型肝炎病毒诱导的髓源性抑制细胞通过信号转导和转录激活因子3途径调节T细胞分化和功能。
Immunology. 2016 Aug;148(4):377-86. doi: 10.1111/imm.12616. Epub 2016 Jun 22.

引用本文的文献

1
The role of interleukin-17 in inflammation-related cancers.白细胞介素-17在炎症相关癌症中的作用。
Front Immunol. 2025 Jan 21;15:1479505. doi: 10.3389/fimmu.2024.1479505. eCollection 2024.
2
The role of proinflammatory cytokines and CXC chemokines (CXCL1-CXCL16) in the progression of prostate cancer: insights on their therapeutic management.促炎细胞因子和 CXC 趋化因子(CXCL1-CXCL16)在前列腺癌进展中的作用:对其治疗管理的深入了解。
Cell Mol Biol Lett. 2024 May 14;29(1):73. doi: 10.1186/s11658-024-00591-9.
3
STAT3 and Its Pathways' Dysregulation-Underestimated Role in Urological Tumors.
STAT3 及其信号通路失调在泌尿系统肿瘤中的被低估作用。
Cells. 2022 Sep 27;11(19):3024. doi: 10.3390/cells11193024.
4
Myeloid-Derived Suppressor Cells as Key Players and Promising Therapy Targets in Prostate Cancer.髓源性抑制细胞作为前列腺癌的关键参与者和有前景的治疗靶点
Front Oncol. 2022 Jul 4;12:862416. doi: 10.3389/fonc.2022.862416. eCollection 2022.
5
CD33 Expression on Peripheral Blood Monocytes Predicts Efficacy of Anti-PD-1 Immunotherapy Against Non-Small Cell Lung Cancer.外周血单核细胞 CD33 表达预测抗 PD-1 免疫治疗对非小细胞肺癌的疗效。
Front Immunol. 2022 Apr 14;13:842653. doi: 10.3389/fimmu.2022.842653. eCollection 2022.
6
Barriers to Immunotherapy in Ovarian Cancer: Metabolic, Genomic, and Immune Perturbations in the Tumour Microenvironment.卵巢癌免疫治疗的障碍:肿瘤微环境中的代谢、基因组和免疫扰动
Cancers (Basel). 2021 Dec 11;13(24):6231. doi: 10.3390/cancers13246231.